Seidel-Dugan Cynthia
Known title: Chief Scientific OfficerCIK: 0001857799
Associated companies
Transaction History
| HOWL | ▲ Buy | Option Exercise | 24,199 | $38K | 1/12/2022 | View on chart |
| HOWL | ▲ Buy | Option Exercise | 15,532 | $74K | 1/12/2022 | View on chart |
| HOWL | ▲ Buy | Option Exercise | 24,199 | $38K | 1/12/2022 | View on chart |
| HOWL | ▲ Buy | Option Exercise | 15,532 | $74K | 1/12/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
No Relevant News for HOWL in Last Week
The only news item in the last week concerns HALO's expanded collaboration with ARGX. This development does not involve Werewolf Therapeutics, so it has no direct impact on HOWL's operations or outlook. Investors may focus on the company's own pipeline and financials for guidance.
No Relevant News for HOWL in Last Week. The only news item in the last week concerns HALO's expanded collaboration with ARGX. This development does not involve Werewolf Therapeutics, so it has no direct impact on HOWL's operations or outlook. Investors may focus on the company's own pipeline and financials for guidance.